Management of localized prostate cancer in men over 65 years

Current Opinion in Urology

Volumn 19, Issue 3, 2009, Pages 309-314

  Cooperberg, Matthew R ^a   Konety, Badrinath R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

Aged; Health services research; Prostate neoplasms; Screening

Indexed keywords

FINASTERIDE;

AGE; ANDROGEN DEPRIVATION THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COMORBIDITY; DIETARY INTAKE; HUMAN; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; AGED; EPIDEMIOLOGY; HEALTH SURVEY; MALE; MASS SCREENING; PATIENT SELECTION; PROSTATE TUMOR; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; MALE; MASS SCREENING; PATIENT SELECTION; PROSTATIC NEOPLASMS; RISK FACTORS; SELECTION BIAS; SENTINEL SURVEILLANCE;

EID: 67649713132     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e328329a303     Document Type: Review

References (41)

1. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005. 2008 [Based on November 2007 SEER data submission]. Available from: http://seer.cancer.gov/csr/1975-2005 [accessed December 20, 2008].
2. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178 (3 Pt 2):S14-S19. (Pubitemid 47224952)
3. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. J Am Med Assoc 2005; 293:2095-2101. (Pubitemid 40617061)
4. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177:2106-2131. (Pubitemid 46726449)
5. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148:435-448. This is a comprehensive literature review commissioned by the national Agency for Healthcare Research and Quality, which reaches the dissatisfying but accurate conclusion that insufficient high-quality evidence exists to determine the relative superiority of one treatment modality over another, either in terms of oncologic cure or quality of life outcomes. (Pubitemid 351665443)
6. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:185-191. The USPSTF is the organization to which primary care providers look most commonly to guide their screening practices. While this position study does not present new data or analyses, and may not be in agreement with the views of many clinicians treating prostate cancer, it is important to be familiar with the rationale against screening elderly patients, and to consider the extent to which overtreatment of low-risk disease is driving these recommendations.
7. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007; 25:3576-3581. (Pubitemid 47372594)
8. Alibhai SM, Leach M, Tomlinson GA, et al. Is there an optimal comorbidity index for prostate cancer? Cancer 2008; 112:1043-1050.
9. Whitson JM, Konety BR. Should men over the age of 65 years receive PSA screening? Argument in favor. Nat Clin Pract Urol 2008; 5:230-231. (Pubitemid 351663412)
10. Tewari A, Johnson CC, Divine G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 2004; 171:1513-1519. (Pubitemid 38365408)
11. Cowen ME, Halasyamani LK, Kattan MW. Predicting life expectancy in men with clinically localized prostate cancer. J Urol 2006; 175:99-103. (Pubitemid 41797102)
12. Konety BR, Sharp VJ, Raut H, Williams RD. Screening and management of prostate cancer in elderly men: the Iowa Prostate Cancer Consensus. Urology 2008; 71:511-514. This study presents a set of concrete recommendations for screening men over 75 formulated by a panel representing a broad range of generalist and specialist providers. The intent of the consensus statement, like that of the USPSTF, is to reduce overscreening and subsequent overtreatment. However, unlike the USPSTF statement, these more detailed recommendations account for patient-risk factors, life expectancy, treatment preferences, and screening history, and are therefore less likely to result in missed diagnoses of high-risk tumors among older men in otherwise good health.
13. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. J AmMed Assoc 2006; 296:2336-2342. (Pubitemid 44749361)
14. Konety BR, Raut H, Smith BJ, et al. Effect of uniform consensus recommendations for PCa screening in older population: differential effects and perceptions of healthcare providers and patients. Urology 2008; 26:431-436.
15. Carter HB, Landis PK, Metter EJ, et al. Prostate-specific antigen testing of older men. J Natl Cancer Inst 1999; 91:1733-1737. (Pubitemid 29518768)
16. Cooperberg MR, Lubeck DP, Meng MV, et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22:2141-2149.
17. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006; 98:1134-1141. (Pubitemid 44288788)
18. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95:981-989.
19. Krupski TL, Smith MR, Lee WC, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer 2004; 101:541-549. (Pubitemid 38970605)
20. Tsai HK, Chen MH,McLeod DG, et al. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 2006; 107:2597-2603. (Pubitemid 44845613)
21. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008; 113:1097-1106.
22. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98:839-845. (Pubitemid 43932049)
23. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. J Am Med Assoc 2008; 300:173-181. Primary androgen deprivation monotherapy is used very commonly for elderly men with localized prostate cancer. This study makes a compelling case that this treatment approach is effective only in high-risk cases, and is likely harmful for low-risk cases. Risk assessment is difficult in SEER given the lack of PSA and Gleason score data, but the instrumental variables approach should compensate for these deficiencies to an extent.
24. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100:1144-1154. An update of the only ongoing randomized trial comparing local therapy - in this case radical prostatectomy - to watchful waiting. The study, comprising mostly patients with symptomatic disease, has shown a survival benefit for prostatectomy, but the benefit may be limited for men over age 65 at time of diagnosis.
25. Alibhai SM, Naglie G, Nam R, et al. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 2003; 21:3318-3327.
26. Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005; 97:1525-1532. (Pubitemid 41631952)
27. Dall'Era MA, Cooperberg MR, Chan JM, et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112:1650-1659. A useful review of the current state of the field with respect to active surveillance for localized prostate cancer.
28. Suardi N, Capitanio U, Chun FK, et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008; 113:2068-2072.
29. Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol 2007; 178 (3 Pt 1):826-831; discussion 31-32
30. Kattan MW, Eastham JA, Wheeler TM, et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170:1792-1797.
31. Dong F, Kattan MW, Steyerberg EW, et al. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; 180:150-154; discussion 4.
32. Albers MJ, Bok R, Chen AP, et al. Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 2008; 68:8607-8615.
33. Samaratunga H, Epstein JI. What is the molecular pathology of low-risk prostate cancer? World J Urol 2008.
34. Ahmed HU, Emberton M. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? World J Urol 2008; 26:457-467.
35. Thompson IM, Tangen CM, Parnes HL, et al. Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology 2008; 71:854-857. One ongoing question with respect to interpretation of the results of the PCPT has been whether finasteride is truly preventing cancer vs. actually treating low-grade disease. This updated analysis, finding a similar reduction in disease incidence across the range of prostate cancer risk in the cohort, suggests that the answer may in fact be both.
36. Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 2005; 174:1065-1069; discussion 9-70. (Pubitemid 41140682)
37. Ornish D, Magbanua MJ, Weidner G, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A 2008; 105:8369-8374. An intriguing study finding evidence that diet and lifestyle modification can effect measurable, reproducible changes in gene expression within prostate cancer cells. (Pubitemid 351904762)
38. Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc [Epub ahead of print]. doi: 10.1111/j.1532-5415.2008.02091.x.
39. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005; 23:5814-5830. (Pubitemid 46300178)
40. Konety BR, Cowan JE, Carroll PR. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol 2008; 179:1797-1803.
41. Alibhai SM, Krahn MD, Cohen MM, et al. Is there age bias in the treatment of localized prostate carcinoma? Cancer 2004; 100:72-81.